- Home
- MAS vs GMAB Comparison
MAS vs GMAB Comparison
Compare MAS & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAS
- GMAB
- Stock Information
- Founded
- MAS 1929
- GMAB 1999
- Country
- MAS United States
- GMAB Denmark
- Employees
- MAS N/A
- GMAB N/A
- Industry
- MAS Industrial Specialties
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- MAS Industrials
- GMAB Health Care
- Exchange
- MAS Nasdaq
- GMAB Nasdaq
- Market Cap
- MAS 14.5B
- GMAB 13.2B
- IPO Year
- MAS N/A
- GMAB N/A
- Fundamental
- Price
- MAS $73.54
- GMAB $23.31
- Analyst Decision
- MAS Buy
- GMAB Buy
- Analyst Count
- MAS 14
- GMAB 7
- Target Price
- MAS $74.36
- GMAB $37.60
- AVG Volume (30 Days)
- MAS 2.8M
- GMAB 1.2M
- Earning Date
- MAS 07-31-2025
- GMAB 08-07-2025
- Dividend Yield
- MAS 1.69%
- GMAB N/A
- EPS Growth
- MAS N/A
- GMAB 77.72
- EPS
- MAS 3.76
- GMAB 21.62
- Revenue
- MAS $7,663,000,000.00
- GMAB $3,646,881,232.00
- Revenue This Year
- MAS N/A
- GMAB $21.64
- Revenue Next Year
- MAS $3.81
- GMAB $15.57
- P/E Ratio
- MAS $19.56
- GMAB $10.54
- Revenue Growth
- MAS N/A
- GMAB 32.97
- 52 Week Low
- MAS $56.55
- GMAB $17.24
- 52 Week High
- MAS $86.70
- GMAB $27.94
- Technical
- Relative Strength Index (RSI)
- MAS 69.27
- GMAB 59.73
- Support Level
- MAS $68.31
- GMAB $21.00
- Resistance Level
- MAS $74.74
- GMAB $22.90
- Average True Range (ATR)
- MAS 1.83
- GMAB 0.46
- MACD
- MAS 0.49
- GMAB 0.08
- Stochastic Oscillator
- MAS 87.43
- GMAB 92.79
About MAS Masco Corporation
Masco manufactures a variety of home improvement and building products. The company's $5-billion plumbing segment, led by the Delta and Hansgrohe brands, sells faucets, showerheads, and other related plumbing fixtures and components. The roughly $3-billion decorative architectural segment primarily sells paints and other coatings under the Behr and Kilz brands, but it also sells builder hardware products.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.